Sai Parenterals has secured ₹122.6 crore from anchor investors ahead of its initial public offering (IPO), signaling strong institutional confidence in the pharmaceutical company. The IPO is scheduled to open for public subscription on March 24, 2026.
The offering comprises both a fresh issue and an offer for sale (OFS) component, with share prices fixed in the band of ₹372 to ₹392 per share. Anchor investor participation at this level indicates robust demand from institutional players for the company’s shares.
Sai Parenterals plans to utilize the IPO proceeds for capacity expansion and research and development (R&D) initiatives. These investments are expected to strengthen the company’s manufacturing capabilities and enhance its product pipeline in the parenteral formulations segment.
The pharma company’s focus on expanding production capacity and R&D aligns with growing demand for injectable medications and parenteral solutions in India’s healthcare sector. The strong anchor investor response reflects market appetite for pharmaceutical companies with expansion plans and innovation focus.
The IPO launch comes as Indian pharmaceutical companies continue to attract investor interest through public market offerings. The subscription period for retail and other investors will follow the anchor allotment, with further details expected as the listing date approaches.
Source: Read original